Cantor sees favorable Tourette’s readout for Neurocrine by end of year

Cantor Fitzgerald analyst Charles Duncan believes the T-Force Gold study benefits from the past experience Neurocrine Biosciences has in Tourette’s syndrome. The study will read out as “interpretable, and favorable” by the end of 2018 to support a supplemental new drug application possibly in the first half of 2019, Duncan tells investors in a research note. The analyst keeps an Overweight rating on Neurocrine with a $150 price target.
https://thefly.com/landingPageNews.php?id=2790519